Antibody-drug conjugates (ADCs) are a relatively new type of medicine for breast cancer. Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Dato-DXd (brand name: Datroway) are two ADCs used to treat breast cancer. Dr Benjamin Schrank and colleagues have developed a new type of ADC that combines an antibody with a toxin — called an antibody-toxin conjugate — that teaches the immune system to recognize and attack cancer cells. Listen to the episode to hear Dr. Schrank explain: the antibody and the toxin component of the medicine how the new medicine works possible side effects next steps for the research Episode image photo credit: The University of Texas MD Anderson Cancer Center

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related